



Full Year Results

Year to 31 March 2024

Dr Huw Jones, CEO

Toni Haenninen, CFO

Dr Helen Kuhlman, CBO

AIM: TCF.L
NOMAD: Cavendish
IR: Instinctif, CAG



Disclaimer

The communication of this presentation may be restricted by law; it is not intended for distribution to, or use by any person in any jurisdiction where such distribution or use would be unlawful. Any person into whose possession any part of this presentation comes is required by Theracryf plc (the "Company") to inform himself/herself about and to observe any applicable restrictions in his/her respective jurisdiction. This presentation is for information purposes only and does not constitute an offer of, or a solicitation to purchase or subscribe for, any securities in which such offer or solicitation is unlawful or to any person to whom it is unlawful to make such offer or solicitation. This presentation or any part of it or the fact of its distribution shall not form the basis of, or be relied on in connection with, any contract commitment or investment decision in relation thereto nor does it constitute a recommendation regarding the securities of the Company. No person must construe the information contained in this presentation as legal, business, tax or investment advice. Investors and prospective investors in the securities of the Company are required to make their own independent investigation and appraisal of the business and financial condition of the Company and the nature of the securities, and consult his/her own independent counsel, business advisor, tax advisor, investment advisor or any other authorised advisors as to the legal, business, tax, investment or any other matters pertaining to the Company and the securities of the Company.

The statements contained in this presentation are made as at the date of this presentation. The distribution of this presentation shall under no circumstances imply that there shall not be a change in the Company's affairs since the date of this presentation or that the information contained in this presentation is correct as of any date subsequent to the date of this presentation. The Company or any member, employee, counsel, officer, director, representative, agent or affiliate of the Company does not have any obligation to update or otherwise revise any statements reflecting circumstances arising after the date of this presentation. To the extent permitted by applicable law, no representation or warranty, express or implied, is made by the Company or any member, employee, counsel, officer, director, representative, agent or affiliate of the Company as to the accuracy or completeness of any information contained in this presentation. No information contained in this presentation is, or shall be relied upon by any person as to its accuracy or completeness or as a promise or representation by the Company. The Company expressly disclaims any and all liability that may be based on any information contained in this presentation and any errors or omissions herein. No person is authorised to give any information not contained in this presentation and any information not contained in this presentation must not be relied upon as having been authorised by or on behalf of the Company.


Nothing contained in this presentation shall be deemed to be a profit forecast. This presentation may contain certain forward-looking statements, beliefs or opinions with respect of the financial condition and business operations of the Company as well as certain plans and objectives of the Company. By their nature, forward-looking statements involve risk and uncertainty, because they depend on circumstances and events that may or may not occur in the future. Past performance of the Company cannot be relied on as a guide to future performance, and any actual results and developments may differ materially from those expressed in or implied by such forward-looking statements. The Company can give no assurance that such expectations will prove to have been correct and the Company therefore cautions any person not to place undue reliance on these forward-looking statements which speak only as at the date of this presentation.



MISSION

To build a drug development powerhouse in profitable segments within oncology and behavioural brain disorders





- **Grant awarded** by the Netherlands government administered by Dutch Cancer Society
 - Pre-clinical work and a clinical trial in glioblastoma (GBM) led by Dr Marjolein Geurts, Erasmus MC, Rotterdam, €1.1m project
 - Activity of SFX-01 in GBM cells from Netherlands' patients corroborating previous data from academic partners in Italy and New Zealand
- **Full clinical study report** issued for the SFX-01 Phase 1b study confirming PK profile and absence of SAEs for commercial grade formulation
- **Evidence of activity of SFX-01** observed in models of colon cancer (University of Michigan, USA) and further SFX-01 activity seen *in vivo* in models of rare childhood cancer rhabdomyosarcoma (La Sapienza University, Rome)
- **Partners:** Constructive discussions continue with Stalicia SA on dispute resolution
- **Board changes**
 - Dr Susan Foden appointed Chair, succeeding Barry Clare following his retirement from board
 - CFO Toni Hänninen appointed as Executive Director, Dr Alan Barge appointed Senior Independent Non-executive Director; Susan Clement-Davies retired from board. Richard Moulson retired from board.

Financial performance in-line with expectations:

	Year to 31 March 2024	Prior Year
Post tax loss	£3.1m	£4.0m
Cash outflow	£3.4m	£4.9m
Cash and short-term investments	£2.0m*	£5.0m

Post period Highlights

- **Acquisition** of Chronos Therapeutics Ltd adding substantial pre-clinical neuropsychiatry portfolio effective 5 April 2024; integration progressing well
 - Adds addiction/anxiety/fatigue programmes in resurgent areas for pharma
- **Company name change** to TheraCryf plc and ticker symbol change to TCF effective 26 April 2024
- **£0.9m raised** in a placing and retail offer; management and board invested c.10% of the raise

Item	Outlook
GBM	Regulatory work and approvals in support of GBM clinical trial via the grant to Erasmus MC, Rotterdam
Acquisition	Completion of integration of Chronos Therapeutics Ltd
Funding	Non-dilutive Grants sought for acquired Ox-1 and DAT programmes
Patents	Grant of further patents for former Chronos programmes
Publications	Publication of clinical paper on SFX-01 Phase 1b pharmacokinetic study
SFX-01 Data	Further PD data from SFX-01 Phase 1b study



Resurgence of neuroscience Q4 2023



AbbVie pads neuroscience portfolio with \$8.7B deal to acquire Cerevel

[Annalee Armstrong](#)



As J&J outlines bullish pipeline goals, neuroscience pipeline takes a starring role

By [Max Bayer](#)



[HEALTH AND SCIENCE](#)

Karuna Therapeutics surges 47% after Bristol Myers Squibb announces \$14 billion deal

Published Dec 22, 2023

[Ashley Capoot](#)



Indivior Enters Into an Exclusive Global License Agreement for C4X Discovery's Orexin-1 (OX1) Antagonist Program for \$294m





AZ buys into Eolas' anti-addiction programme in \$145m deal



Axsome Therapeutics Enters into License Agreement with Pharmanovia to Expand Commercialization and Further Develop Sunosi® (solriamfetol) in Europe

Published: Feb 22, 2023

Group Pipeline



* Orphan Conditions

TheraCryf Management and Board



Dr Huw Jones
CEO

Over 30 years' experience of leadership in public and private R&D-based companies within the biotechnology and pharmaceutical sector. Huw is also a non-executive director of biotech industry body OBN. Ashbourne, CVT, Elan, SB (GSK)



Toni Haenninen
CFO

Over 20 years' experience of financial leadership in public and private companies in the US, APAC and Europe: Danaher Group, Faron Pharmaceuticals



Dr Sue Foden
Chair

Executive Chair of QBiotics Group Ltd and an NED on the board of Laverock Therapeutics Ltd. She is a member of the Investment Committee of CD3, the joint drug discovery initiative between the University of Leuven & the European Investment Fund (EIF), and a Trustee of the Roslin Foundation.



Dr Alan Barge
NED

Former CMO of ASLAN Pharmaceuticals and former VP and Head of Oncology and infection at AZ.



Chronos Nominee
NED

Under the agreement Chronos has the right to nominate one NED subject to Evgen Board approval.



Dr Nicholas Mallard
VP - Project Management

Over 30 years' experience in research and early/late phase development spanning large pharma (Takeda, AZ, Scherer DDS), biotech (Oxford Glycosciences, Amarin Neuroscience, Shield Therapeutics) and several CROs.



Dr Helen Kuhlman
CBO

Over 20 years' experience in government funding and equity investment together with scientific and business roles in public and private R&D-based biotechnology companies



Dr Glen Clack
CMO

Over 25 years' experience in oncology drug development with a specialism in translational medicine. AZ, multiple small Biotech Co's




A Transformative year

Non-dilutive funding in GBM
Characterisation of SFX-01 in volunteers
Expanded, risk-adjusted portfolio

Thank You

TheraCryf plc
enquiries@theracryf.com
www.theracryf.com






TheraCryf

APPENDIX

TheraCryf plc
enquiries@theracryf.com
www.theracryf.com





Clinical stage

- Developing a new class of pharmaceuticals - based on **highly biologically active “sulforaphane”** - applications in multiple therapeutic areas based on a network of targets
- Platform stabilisation technology, **extensive IP** for platform and lead asset SFX-01. **Orphan drug designation in USA**
- Internal programme – **glioblastoma (GBM)** the most fatal of the brain cancers. **Clinical POC is grant funded** by Dutch cancer society
- **Out-license deal with Stalicia SA** in neurodevelopmental disorders. \$160.5m milestones, double digit royalty
- **Phase1b study on commercial grade tablet** complete with further *post hoc* genomic analysis in Q3 2024
- First clinical **read out in GBM 2026**



Late Pre-clinical stage

- Spin out of Oxford University, lifetime raise £15.4m
- 2016 acquisition of **3 NCE assets from Shire** with CNS, neurology/psychiatry focus
- 2 Assets developed to late pre-clinical by Chronos
- Main programmes
 - **Ox1 antagonist** (anxiety and addictive disorders, BED) **class leading profile**
 - DAT inhibitor (fatigue, long COVID, MS fatigue, narcolepsy) **atypical, unique**
- **Patents granted** in major territories including USA, Ox1 patent valid until 2038
- Entry to Phase 1 clinical studies as early as 2026, early clinical **POC 2026/7***

* Subject to separate funding



Rationale for Combination

- More than **triples the size of the TheraCryf portfolio**
- Capitalising on **renewed interest** and deal activity in Neuroscience
- Chronos neuropsychiatry assets are **complementary** to Evgen's neurodevelopmental disorders and brain cancer asset
- Evgen has the expertise to develop and commercialise the combined portfolio
- Multiple **potential inflection points**
- **High quality investor base in Chronos**



Transaction Details

Low upfront, de-risked and back-weighted

- **Acquisition of entire issued share capital of Chronos Therapeutics**
 - Single share class, no warrants, no debt, on a cash and debt free basis
- **£1m in Evgen shares upfront to Chronos shareholders***
 - Includes Vulpes, Odey, Oxford University, WA Capital, Takeda, HNWs
 - Chronos shareholders locked in for 18 months
- **£1m in shares or loan at Evgen's discretion on start of first Phase 1 clinical trial**
- **£1.5m in shares or loan at Evgen's discretion on end of first successful Phase 1 clinical trial**
- **10% of first three milestones of any out-licensing transaction involving of a former Chronos asset, capped**
 - Payment in shares or loan notes at Evgen's discretion

